Amylyx Pharmaceuticals Inc (AMLX)
1.72
+0.04
(+2.38%)
USD |
NASDAQ |
May 31, 16:00
1.72
0.00 (0.00%)
After-Hours: 20:00
Amylyx Pharmaceuticals Enterprise Value: -256.32M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | -256.32M |
| May 30, 2024 | -259.04M |
| May 29, 2024 | -259.72M |
| May 28, 2024 | -257.00M |
| May 24, 2024 | -255.64M |
| May 23, 2024 | -252.24M |
| May 22, 2024 | -248.84M |
| May 21, 2024 | -250.88M |
| May 20, 2024 | -248.16M |
| May 17, 2024 | -248.84M |
| May 16, 2024 | -248.84M |
| May 15, 2024 | -249.52M |
| May 14, 2024 | -246.12M |
| May 13, 2024 | -249.52M |
| May 10, 2024 | -253.94M |
| May 09, 2024 | -244.76M |
| May 08, 2024 | -242.04M |
| May 07, 2024 | -239.32M |
| May 06, 2024 | -237.96M |
| May 03, 2024 | -235.24M |
| May 02, 2024 | -237.28M |
| May 01, 2024 | -242.04M |
| April 30, 2024 | -250.20M |
| April 29, 2024 | -244.08M |
| April 26, 2024 | -253.60M |
| Date | Value |
|---|---|
| April 25, 2024 | -252.24M |
| April 24, 2024 | -245.44M |
| April 23, 2024 | -240.68M |
| April 22, 2024 | -238.64M |
| April 19, 2024 | -246.12M |
| April 18, 2024 | -238.64M |
| April 17, 2024 | -237.28M |
| April 16, 2024 | -236.60M |
| April 15, 2024 | -232.52M |
| April 12, 2024 | -230.48M |
| April 11, 2024 | -217.63M |
| April 10, 2024 | -206.07M |
| April 09, 2024 | -191.80M |
| April 08, 2024 | -190.44M |
| April 05, 2024 | -195.20M |
| April 04, 2024 | -195.88M |
| April 03, 2024 | -194.52M |
| April 02, 2024 | -195.20M |
| April 01, 2024 | -189.08M |
| March 31, 2024 | -180.24M |
| March 28, 2024 | -178.86M |
| March 27, 2024 | -176.15M |
| March 26, 2024 | -185.64M |
| March 25, 2024 | -187.67M |
| March 22, 2024 | -185.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-259.72M
Minimum
May 29 2024
2.439B
Maximum
Dec 01 2022
1.079B
Average
1.082B
Median
Enterprise Value Benchmarks
| iRhythm Technologies Inc | 2.819B |
| Cassava Sciences Inc | 933.71M |
| Bristol-Myers Squibb Co | 129.36B |
| Moderna Inc | 46.11B |
| ACADIA Pharmaceuticals Inc | 2.021B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -118.79M |
| Revenue (Quarterly) | 88.64M |
| Total Expenses (Quarterly) | 210.77M |
| EPS Diluted (Quarterly) | -1.75 |
| Gross Profit Margin (Quarterly) | -31.32% |
| Profit Margin (Quarterly) | -134.0% |
| Earnings Yield | -62.21% |
| Normalized Earnings Yield | -62.21 |